IP Library Granted Patent US 7,838,019
Granted Patent B2
US 7,838,019 · App. 10/550,026 · Granted Nov 23, 2010

Composition comprising iscom particles and live micro-organisms

Assignee: Isconova AB
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,838,019
App. No.
10/550,026
Granted
Nov 23, 2010
Kind
B2
Abstract

Iscom particles can be used as an adjuvant for preparing of an antigenic composition which comprises live micro-organisms and/or killed micro-organisms and/or antigenic molecules. A composition may comprise at least one iscom particle and one or more live micro-organisms and/or killed micro-organisms and/or antigenic molecules. A kit can comprise at least one compartment containing at least one living organism and at least one compartment containing at least one iscom particle.

Claims (23)

1. A method of preparing an antigenic composition, comprising mixing an iscom particle and at least one live micro-organism, wherein the iscom particle is used as an adjuvant.

2. The method according to claim 1 , wherein the antigenic composition is a vaccine comprising at least one live virus.

3. The method according to claim 1 , wherein the antigenic composition further comprises at least one killed or inactivated micro-organism.

4. The method according to claim 1 , wherein the antigenic composition further comprises at least one antigenic molecule.

5. The method according to claim 1 , wherein the iscom particle is an iscom comprising at least one glycoside, at least one lipid and at least one hydrophobic protein or peptide-containing antigen.

6. The method according to claim 1 , wherein the iscom particle is an iscom-matrix, comprising at least one glycoside and at least one lipid.

7. The method according to claim 1 , wherein the iscom particle comprises at least one glycoside fragment from Quillaja Saponaria Molina.

8. The method according to claim 7 , wherein the iscom particle comprises at least one of Fraction A and Fraction C of Quillaja Saponaria Molina.

9. Composition comprising at least one iscom particle and at least one living micro-organism.

10. Composition according to claim 9 , wherein the living micro-organism is a virus.

11. Composition according to claim 9 , further comprising at least one killed or inactivated micro-organism.

12. Composition according to claim 9 , further comprising at least one antigenic molecule.

13. Composition according to claim 9 , wherein the iscom particle comprises at least one glycoside fragment from Quillaja Saponaria Molina.

14. Composition according to any of claims 9 - 13 , wherein the iscom particle comprises at least one of Fraction A and Fraction C of Quillaja Saponaria Molina.

15. Composition according to claim 9 , further comprising a pharmaceutically acceptable carrier, diluent, excipient or additive.

16. The method according to claim 1 , wherein the method includes providing a kit of parts comprising at least one compartment containing the at least one live micro-organism and at least one compartment containing the iscom particle.

17. The composition according to claim 9 , wherein the iscom particle is an iscom comprising at least one glycoside, at least one lipid and at least one hydrophobic protein or peptide-containing antigen.

18. The composition according to claim 9 , wherein the iscom particle is an iscom-matrix, comprising at least one glycoside and at least one lipid.

19. The method according to any of claims 1 - 6 , wherein a plurality of the iscom particles comprise a first iscom particle and a second iscom particle, the first iscom particle comprising a first fraction of Quillaja Saponaria Molina and not a second fraction of Quillaja Saponaria Molina, and the second iscom particle comprising the second fraction of Quillaja Saponaria Molina and not the first fraction of Quillaja Saponaria Molina.

20. The composition according to any of claim 9 - 12 or 17 - 18 , wherein a plurality of the iscom particles comprise a first iscom particle and a second iscom particle, the first iscom particle comprising a first fraction of Quillaja Saponaria Molina and not a second fraction of Quillaja Saponaria Molina, and the second iscom particle comprising the second fraction of Quillaja Saponaria Molina and not the first fraction of Quillaja Saponaria Molina.

21. The composition according to claim 9 , wherein the composition may be used for humans.

22. The composition according to claim 9 , the composition not reducing proliferation of the live micro-organism in a host.

23. The composition according to claim 9 , wherein the composition provides for enhanced immunogenicity of the live micro-organism in a host.

Assignments (2)
CHANGE OF NAME Recorded Nov 21, 2019
From: ISCONOVA AB
To: NOVAVAX AB
Reel/Frame 051075/0473 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 27, 2008
From: MOREIN, BROR; LOVGREN BENGTSSON, KARIN
To: ISCONOVA AB
Reel/Frame 021000/0580 →
Priority Claims (1)
SE 0300795 · Mar 24, 2003 · national
Continuity (1)
Related Publication 20080095795A1 · Apr 24, 2008